Salem Radio Network News Thursday, September 29, 2022

Health

Novartis says lung cancer drug canakinumab failed phase III trial

ZURICH (Reuters) – Novartis said on Monday its canakinumab drug to help treat non-small cell lung cancer failed a phase III trial.

The drug, used as an adjuvant treatment, did not meet its primary endpoint of disease-free survival, the Swiss company said.

(Reporting by John Revill; Editing by Christian Schmollinger)

Previous
Next

Editorial Cartoons

View More »

Steve Breen
Fri, Sep 23, 2022

X CLOSE